Noxxon adds to venture backers with €33M round

In an unusually large round for a European biotech, Berlin's Noxxon Pharma raised €33 million ($40 million) in a Series D that attracted a long lineup of European venture funds.

New investor NGN Capital spearheaded the round, leading a pack that included existing investors TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin GmbH, Dow Venture Capital, FCP OP MEDICAL BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH, the Dieckell Group, and others.

Noxxon plans to use the money to fund the clinical and preclinical work needed on its three key drug candidates. The developer touts its Spiegelmer technology for finding oligonucleotide-based drugs; high-potency inhibitors that are both extremely stable with an extremely low potential for toxicity or immune system side effects. Its first three targets are in diabetes, oncology and hematology.   

"This investment provides Noxxon with the funds to advance the clinical development of our three most advanced in-house programs without the need for additional external support," says CEO Dr. Frank Morich.

- read Noxxon's release for more info

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.